An official website of the United States government
Home
Name
Ponatinib
Alternate Names
Iclusig
Abbreviations
None
Category
Chemotherapy
Subcategory
kinase inhibitor
NSC Number
None
Primary Site
Histology
None
Remarks
March 22, 2024 FDA granted accelerated approval to Iclusig (ponatinib) with chemotherapy for adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
March 19, 2024 Following FDA request to suspend marketing of ponatinib (Iclusig) October 2013, this drug has now
received accelerated approval with chemotherapy for adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Ponatinib received FDA approval December 14, 2012.
Important note October 31, 2013: The FDA has asked the manufacturer of Iclusig to suspend marketing and sales of the drug because of life-threatening blood clots and severe narrowing of blood vessels.
December 12, 2016: Ponatinib received full FDA approval for treatment of adult patients with chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL).
March 19, 2024 Following FDA request to suspend marketing of ponatinib (Iclusig) October 2013, this drug has now
received accelerated approval with chemotherapy for adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Ponatinib received FDA approval December 14, 2012.
Important note October 31, 2013: The FDA has asked the manufacturer of Iclusig to suspend marketing and sales of the drug because of life-threatening blood clots and severe narrowing of blood vessels.
December 12, 2016: Ponatinib received full FDA approval for treatment of adult patients with chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL).
Coding
This drug should be coded
